Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
10/2007
10/02/2007US7276518 For therapy of neuropathic or chronic pain
10/02/2007US7276514 Prevent tissue damage prevent stroke, headaches
10/02/2007US7276513 Steroidal compounds for inhibiting steroid sulphatase
10/02/2007US7276511 E.g., N-{2-(3,4-dichlorophenyl)-2-[(3,3-diphenylpropionyl)-methylamino]-4-{spiro[benzo(c)thiophene-1(3H),4'-piperidine]-(2S)-oxide}-1'-yl-butyl}-3,3,3-trifluoro-N-methyl-propionamide hydrochloride, NK-1 or NK-2 receptor antagonists; used to treat irritable bowel syndrome, pain, anxiety and vomiting
10/02/2007US7276509 Substance P; 2-(phenyl)-4-(3-oxo-piperazin-1-yl-)-piperidine-1-carboxylic acid; benzyl-methylamide; antagonists of the NK1 receptor; antidepressant, antiolytic; antiemetic
10/02/2007US7276508 Indole derivatives useful for the treatment of CNS disorders
10/02/2007US7276504 Nasally administering an imidazotriazinone substituted with an (alkoxy)(aminosulfonyl)phenyl group for treating diseases including psoriasis, female infertility, diabetes, glaucoma, cystic fibrosis, pre-eclampsia, Parkinsonism, tinnitus, pain, gastric motility disorders, and pulmonary hypertension
10/02/2007US7276503 Administration of optically pure (S,S) reboxetine, or a salt thereof; diminished adverse side effects
10/02/2007US7276500 Substituted amides, their preparation and use
10/02/2007US7276496 Cyclic malonamides as inhibitors of Aβ protein protection
10/02/2007US7276495 Substituted lactams as inhibitors of Aβ protein production
10/02/2007US7276250 Sustained release formulations of oxymorphone
10/02/2007US7276245 Administering a botulinum toxin
10/02/2007CA2412564C Purine derivatives
10/02/2007CA2401229C Aryl fused azapolycyclic compounds
10/02/2007CA2387357C Derivatives of pyrazolo[4,3-d]pyrimidin-7-ones which inhibit cyclic guanosine 3',5'-monophosphate phosphodiesterase
10/02/2007CA2378613C Selective iglur5 receptor antagonists for the treatment of migraine
10/02/2007CA2378369C Small molecules useful in the treatment of inflammatory disease
10/02/2007CA2298033C Certain 5-alkyl-2-arylaminophenylacetic acids and derivatives
10/02/2007CA2203417C Bisarylcarbinol derivatives as inhibitors of leukotriene biosynthesis
10/02/2007CA2184049C Thermally stable storable crystalline modification of n-methyl-n-[(1s)-1-phenyl-2-((3s)-3-hydroxy-pyrrolidin-1-yl)ethyl]-2,2-diphenylacetamide and a process for its preparation
09/2007
09/27/2007WO2007109783A2 Substituted pyrimidine kinase inhibitors
09/27/2007WO2007109355A2 6,7,8, 9 -tetrahydro- 5h- pyrimido [4, 5-d] azepin-4-yl] -amine derivatives as modulators of trpvl for the treatment of pain
09/27/2007WO2007109289A1 Enantiomerically pure s-etifoxine, pharmaceutical compositions thereof and methods of their use
09/27/2007WO2007109288A2 Enantiomerically pure r-etifoxine, pharmaceutical compositions thereof and methods of their use
09/27/2007WO2007109045A1 Heterocyclic organic compounds for the treatment of in particular melanoma
09/27/2007WO2007108936A2 N-substituted-azacyclylamines as histamine-3 antagonists
09/27/2007WO2007108756A1 Improved protofibril selective antibodies and the use thereof
09/27/2007WO2007108754A1 Crystalline forms of n- {2-tert -butyl -1- [ (4,4- dif luorocyclohexyl) methyl] -lh-benzimidazol-5- yl}ethanesulfonamide salts
09/27/2007WO2007108744A2 Novel quinazolines as 5-ht6 modulators
09/27/2007WO2007108743A2 Novel quinazolines as 5-ht6 modulators ii
09/27/2007WO2007108742A1 Novel tetralins as 5-ht6 modulators
09/27/2007WO2007108695A1 Preparation for prophylactic or therapeutic treatment of lapse of memory
09/27/2007WO2007108557A1 Control of intracellular target molecule by ip3 receptor-binding protein
09/27/2007WO2007108434A1 Expression construct for digesting aggregating protein and method of inhibiting the aggregation of aggregating protein
09/27/2007WO2007108292A1 Neurite elongation inducer
09/27/2007WO2007108071A1 Antistress composition and food and drink containing the same
09/27/2007WO2007108009A1 A process for purification of topiramate
09/27/2007WO2007108002A2 Use of digitalis-like compounds in the treatment of affective disorders
09/27/2007WO2007107846A1 A pharmaceutical composition useful as acetyl cholinesterase inhibitors
09/27/2007WO2007107567A1 Benzimidazoles which have activity at m1 receptor and their uses in medicine
09/27/2007WO2007107566A1 Benzimidazoles which have activity at m1 receptor and their uses in medicine
09/27/2007WO2007107539A1 Compounds which potentiate ampa receptor and uses thereof in medicine
09/27/2007WO2007107469A1 Methods of inhibiting btk and syk protein kinases
09/27/2007WO2007107319A1 Isolation, structure determination, synthesis and bioactivity of damipipecolin and damituricin
09/27/2007WO2007107291A2 Agents for influencing receptors and consequences thereof
09/27/2007WO2007106991A1 Identification of crmp4 as a convergent regulator of axon outgrowth inhibition
09/27/2007WO2007106987A1 Continuous dosing regimens for neural stem cell proliferating agents and neural stem cell differentiating agents
09/27/2007WO2007106986A1 Dosing regimes for lh or hcg and epo for treatment of neurological disorders
09/27/2007WO2007106938A1 Method of treatment or prophylaxis inflammatory pain
09/27/2007WO2007092458A8 Antidotes to exogenous neurotoxic agents
09/27/2007WO2007089715A3 Method for treatment of neuropathic pain
09/27/2007WO2007084557A3 Azaindoles useful as inhibitors of janus kinases
09/27/2007WO2007079929A3 Substituted tricyclic piperidone derivatives
09/27/2007WO2007067495A3 Levodopa prodrug mesylate, compositions thereof, and uses thereof
09/27/2007WO2007023389A3 Polymorphic forms of 3-amino-1-propanesulfonic acid
09/27/2007WO2006124862A3 Methods for the treatment of ocular and neurodegenerative conditions in a mammal
09/27/2007WO2006076317A9 Aminophenyl derivatives as selective androgen receptor modulators
09/27/2007US20070225375 Methods of treating fibromyalgia syndrome, chronic fatigue syndrome and pain
09/27/2007US20070225374 Hydroxypropyl Amides for the Treatment of Alzheimer's Disease
09/27/2007US20070225368 Therapy for Multiple Sclerosis
09/27/2007US20070225349 Substituted 4-(Indazol-3-yl)phenols
09/27/2007US20070225308 2-Amino Quinazoline Derivative
09/27/2007US20070225300 HETEROARYL SUBSTITUTED 2-PYRIDINYL AND 2-PYRIMIDINYL -6,7,8,9-TETRAHYDROPYRIMIDO[1,2-a] PYRIMIDIN-4-ONE DERIVATIVES
09/27/2007US20070225287 Substituted Arylpyrazines
09/27/2007US20070225272 CGRP receptor antagonists
09/27/2007US20070225237 Methods for the prevention and/or the treatment of glutamate cytotoxicity
09/27/2007US20070225236 Methods for the prevention and/or the treatment of glutamate cytotoxicity
09/27/2007US20070225235 Methods for the prevention and/or the treatment of glutamate cytotoxicity
09/27/2007US20070225218 Extracellular Messengers
09/27/2007US20070225214 Use of osteopontin for the treatment and/or prevention of neurologic diseases
09/27/2007US20070224679 Lentiviral triplex DNA, and vectors and recombinant cells containing lentiviral triplex DNA
09/27/2007US20070224656 Modulation of Abeta levels by beta-secretase BACE2
09/27/2007US20070224290 Nutrient supplements and methods for treating autism and for preventing the onset of autism
09/27/2007US20070224265 Tablet Comprising Branched Chain Amino Acid and Method for Producing the Same
09/27/2007US20070224263 Aminoalkylphosphonates and related compounds as Edg receptor agonists
09/27/2007US20070224221 Botulinum toxin neurotoxic component for treating juvenile cerebral palsy
09/27/2007DE60125416T2 Stabilisierte formulierungen von 6-hydroxy-3-(4-(2-(piperidin-1-yl)ethoxy)phenoxy)-2-(4-methoxyphenyl)benzo(b)thiophen und deren salze Stabilized formulations of 6-hydroxy-3- (4- (2- (piperidin-1-yl) ethoxy) phenoxy) -2- (4-methoxyphenyl) benzo (b) thiophene and their salts
09/27/2007DE102006013531A1 Polylactid-Nanopartikel Polylactide nanoparticles
09/27/2007DE102006012876A1 Mittel zur positiven Beeinflussung der Alzheimer Krankheit und/oder zur Alzheimerprophylaxe Means for positively influencing Alzheimer's disease and / or Alzheimer's prevention
09/27/2007DE102006012545A1 Substituierte 2-Amino-4-phenyl-dihydrochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament Substituted 2-amino-4-phenyl-dihydroquinolines, processes for their preparation, their use as a medicament, and medicament containing them
09/27/2007DE102006012544A1 Substituierte 1-Amino 4-phenyl-dihydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament Substituted 1-amino 4-phenyl-dihydroisoquinolines, processes for their preparation, their use as a medicament, and medicament containing them
09/27/2007CA2648829A1 Crystalline forms of n-{2-tert-butyl-1-[(4,4-difluorocyclohexyl)methyl]-1h-benzimidazol-5-yl}ethanesulfonamide salts
09/27/2007CA2647769A1 Control of intracellular target molecule by ip3 receptor-binding protein
09/27/2007CA2646977A1 6,7,8,9 -tetrahydro-5h-pyrimido[4,5-d]azepin-4-yl]-amine derivatives as modulators of trpvl for the treatment of pain
09/27/2007CA2646643A1 Methods for preventing and treating amyloidogenic diseases
09/27/2007CA2646585A1 Compounds which potentiate ampa receptor and uses thereof in medicine
09/27/2007CA2646379A1 Method of treatment or prophylaxis inflammatory pain
09/27/2007CA2646007A1 Enantiomerically pure s-etifoxine, pharmaceutical compositions thereof and methods of their use
09/27/2007CA2645983A1 Identification of crmp4 as a convergent regulator of axon outgrowth inhibition
09/27/2007CA2645731A1 N-substituted-azacyclylamines as histamine-3 antagonists
09/27/2007CA2645583A1 Methods of inhibiting btk and syk protein kinases
09/27/2007CA2645120A1 Treatment of cns conditions
09/27/2007CA2644356A1 Heterocyclic organic compounds for the treatment of in particular melanoma
09/27/2007CA2644116A1 Continuous dosing regimens for neural stem cell proliferating agents and neural stem cell differentiating agents
09/27/2007CA2643502A1 Dosing regimes for lh or hcg and epo for treatment of neurological disorders
09/27/2007CA2630344A1 Improved protofibril selective antibodies and the use thereof
09/26/2007EP1837342A2 Sodium-channel alpha 1-subunit and their polypeptides and their treatment of generalised epilepsy with febrile seizures plus
09/26/2007EP1837034A1 Remedy for alzheimer´s disease
09/26/2007EP1837022A1 Indolomorphinan derivative having carboxy in 6'-position
1 ... 755 756 757 758 759 760 761 762 763 764 765 766 767 768 769 770 771 772 773 774 775 ... 1833